Selected research
Industry Research
Dabigatran Industry Research Report 2026
Market perspective
The global Dabigatran market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Dabigatran market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Dabigatran market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Dabigatran market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Dabigatran include Aspen Holdings, Boehringer Ingelheim, Bristol-Myers Squibb Company, Bayer Healthcare, GlaxoSmithKline, Pfizer and Teva Pharmaceutical Industries, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Dabigatran market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Dabigatran.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Dabigatran Market by Company
Aspen Holdings
Boehringer Ingelheim
Bristol-Myers Squibb Company
Bayer Healthcare
GlaxoSmithKline
Pfizer
Teva Pharmaceutical Industries
Dabigatran Segment by Type
Tablets
Capsule
Others
Dabigatran Segment by Application
Deep Vein Thrombosis
Pulmonary Embolism
Others
Dabigatran Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dabigatran market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dabigatran and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dabigatran.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Dabigatran companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tablets
- Capsule
- Others
Applications
- Deep Vein Thrombosis
- Pulmonary Embolism
- Others
Companies covered
- Aspen Holdings
- Boehringer Ingelheim
- Bristol-Myers Squibb Company
- Bayer Healthcare
- GlaxoSmithKline
- Pfizer
- Teva Pharmaceutical Industries
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Dabigatran by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Tablets
- 2.2.3 Capsule
- 2.2.4 Others
- 2.3 Dabigatran by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Deep Vein Thrombosis
- 2.3.3 Pulmonary Embolism
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Dabigatran Breakdown Data by Type
- 3.1 Global Dabigatran Historic Market Size by Type (2021-2026)
- 3.2 Global Dabigatran Forecasted Market Size by Type (2027-2032)
4 Dabigatran Breakdown Data by Application
- 4.1 Global Dabigatran Historic Market Size by Application (2021-2026)
- 4.2 Global Dabigatran Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Dabigatran Market Perspective (2021-2032)
- 5.2 Global Dabigatran Growth Trends by Region
- 5.2.1 Global Dabigatran Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Dabigatran Historic Market Size by Region (2021-2026)
- 5.2.3 Dabigatran Forecasted Market Size by Region (2027-2032)
- 5.3 Dabigatran Market Dynamics
- 5.3.1 Dabigatran Industry Trends
- 5.3.2 Dabigatran Market Drivers
- 5.3.3 Dabigatran Market Challenges
- 5.3.4 Dabigatran Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Dabigatran Players by Revenue
- 6.1.1 Global Top Dabigatran Players by Revenue (2021-2026)
- 6.1.2 Global Dabigatran Revenue Market Share by Players (2021-2026)
- 6.2 Global Dabigatran Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Dabigatran Head Office and Area Served
- 6.4 Global Dabigatran Players, Product Type & Application
- 6.5 Global Dabigatran Manufacturers Established Date
- 6.6 Global Dabigatran Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Dabigatran Market Size (2021-2032)
- 7.2 North America Dabigatran Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Dabigatran Market Size by Country (2021-2026)
- 7.4 North America Dabigatran Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Dabigatran Market Size (2021-2032)
- 8.2 Europe Dabigatran Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Dabigatran Market Size by Country (2021-2026)
- 8.4 Europe Dabigatran Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Dabigatran Market Size (2021-2032)
- 9.2 Asia-Pacific Dabigatran Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Dabigatran Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Dabigatran Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Dabigatran Market Size (2021-2032)
- 10.2 South America Dabigatran Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Dabigatran Market Size by Country (2021-2026)
- 10.4 South America Dabigatran Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Dabigatran Market Size (2021-2032)
- 11.2 Middle East & Africa Dabigatran Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Dabigatran Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Dabigatran Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Aspen Holdings
- 12.1.1 Aspen Holdings Company Information
- 12.1.2 Aspen Holdings Business Overview
- 12.1.3 Aspen Holdings Revenue in Dabigatran Business (2021-2026)
- 12.1.4 Aspen Holdings Dabigatran Product Portfolio
- 12.1.5 Aspen Holdings Recent Developments
- 12.2 Boehringer Ingelheim
- 12.2.1 Boehringer Ingelheim Company Information
- 12.2.2 Boehringer Ingelheim Business Overview
- 12.2.3 Boehringer Ingelheim Revenue in Dabigatran Business (2021-2026)
- 12.2.4 Boehringer Ingelheim Dabigatran Product Portfolio
- 12.2.5 Boehringer Ingelheim Recent Developments
- 12.3 Bristol-Myers Squibb Company
- 12.3.1 Bristol-Myers Squibb Company Company Information
- 12.3.2 Bristol-Myers Squibb Company Business Overview
- 12.3.3 Bristol-Myers Squibb Company Revenue in Dabigatran Business (2021-2026)
- 12.3.4 Bristol-Myers Squibb Company Dabigatran Product Portfolio
- 12.3.5 Bristol-Myers Squibb Company Recent Developments
- 12.4 Bayer Healthcare
- 12.4.1 Bayer Healthcare Company Information
- 12.4.2 Bayer Healthcare Business Overview
- 12.4.3 Bayer Healthcare Revenue in Dabigatran Business (2021-2026)
- 12.4.4 Bayer Healthcare Dabigatran Product Portfolio
- 12.4.5 Bayer Healthcare Recent Developments
- 12.5 GlaxoSmithKline
- 12.5.1 GlaxoSmithKline Company Information
- 12.5.2 GlaxoSmithKline Business Overview
- 12.5.3 GlaxoSmithKline Revenue in Dabigatran Business (2021-2026)
- 12.5.4 GlaxoSmithKline Dabigatran Product Portfolio
- 12.5.5 GlaxoSmithKline Recent Developments
- 12.6 Pfizer
- 12.6.1 Pfizer Company Information
- 12.6.2 Pfizer Business Overview
- 12.6.3 Pfizer Revenue in Dabigatran Business (2021-2026)
- 12.6.4 Pfizer Dabigatran Product Portfolio
- 12.6.5 Pfizer Recent Developments
- 12.7 Teva Pharmaceutical Industries
- 12.7.1 Teva Pharmaceutical Industries Company Information
- 12.7.2 Teva Pharmaceutical Industries Business Overview
- 12.7.3 Teva Pharmaceutical Industries Revenue in Dabigatran Business (2021-2026)
- 12.7.4 Teva Pharmaceutical Industries Dabigatran Product Portfolio
- 12.7.5 Teva Pharmaceutical Industries Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst